Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2Phase 3 1

Status

Recruiting 4Completed 2Active not recruiting 2

Sponsor Class

NIH 3INDUSTRY 3OTHER 2

Study Type

Interventional 8

Sponsor

Cancer Type

Breast 53Gynecologic 52Genitourinary 35Gastrointestinal 23Thoracic 19Sarcoma 13Other solid neoplasm 11CNS 11Tumor-Agnostic 8Lymphoid 5Endocrine 5NET 4Head & Neck 4Other hematologic neoplasm 3Plasma cell 2Myeloid 2Dermatologic 2Classical hematology 2

Conditions

Neoplasm Metastasis 5Neoplasms, Unknown Primary 1Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 55Specimen Handling 28Biopsy 28Magnetic Resonance Spectroscopy 27Paclitaxel 23Blood Specimen Collection 22Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Bevacizumab 18Surveys and Questionnaires 17Fluorouracil 14Oxaliplatin 13Cisplatin 13Leucovorin 12Cyclophosphamide 12Radiotherapy 11Radiosurgery 11Pemetrexed 11Capecitabine 11Irinotecan 10Gemcitabine 10Docetaxel 10Ipilimumab 9trastuzumab deruxtecan 8olaparib 8durvalumab 8Taxes 8Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
olaparib × Tumor-Agnostic × 1 year × Clear all
NCT04585958 2026-05-20

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
55 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05898399 2026-05-01

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Artios Pharma Ltd

Phase 1/2 Recruiting
181 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03842228 2026-04-29

COD

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04197713 2026-04-29

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

National Cancer Institute (NCI)

Phase 1 Active not recruiting
13 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03976362 2026-02-25

KEYLYNK-008

Merck Sharp & Dohme LLC

Phase 3 Completed
851 enrolled 25 charts
Tumor-Agnostic

Carcinoma

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT02029001 2025-08-07

MOST plus

Centre Leon Berard

Phase 2 Recruiting
900 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡